The Potential of Flavonoids and Flavonoid Metabolites in the Treatment of Neurodegenerative Pathology in Disorders of Cognitive Decline

被引:32
作者
Melrose, James [1 ,2 ,3 ]
机构
[1] Univ Sydney, Inst Bone & Joint Res, Kolling Inst Med Res, Fac Hlth & Sci,Royal North Shore Hosp,Raymond Purv, St Leonards, NSW 2065, Australia
[2] Univ NSW, Grad Sch Biomed Engn, Sydney, NSW 2052, Australia
[3] Univ Sydney, Sydney Med Sch, Royal North Shore Hosp, Northern Campus, St Leonards, NSW 2065, Australia
关键词
therapeutic treatment of neurological disorders; gut-brainaxis; protocatechuic acid; urolithins; gamma-valerolactones; autism; bipolar disorder; Alzheimer's disease; Parkinson's disease; VAGUS NERVE-STIMULATION; TRADITIONAL CHINESE MEDICINE; BRAIN-BARRIER DISRUPTION; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; GUT MICROBIOTA; PROLYL OLIGOPEPTIDASE; ANXIOLYTIC-LIKE; DOUBLE-BLIND; EPIGALLOCATECHIN-3-GALLATE EGCG;
D O I
10.3390/antiox12030663
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Flavonoids are a biodiverse family of dietary compounds that have antioxidant, anti-inflammatory, antiviral, and antibacterial cell protective profiles. They have received considerable attention as potential therapeutic agents in biomedicine and have been widely used in traditional complimentary medicine for generations. Such complimentary medical herbal formulations are extremely complex mixtures of many pharmacologically active compounds that provide a therapeutic outcome through a network pharmacological effects of considerable complexity. Methods are emerging to determine the active components used in complimentary medicine and their therapeutic targets and to decipher the complexities of how network pharmacology provides such therapeutic effects. The gut microbiome has important roles to play in the generation of bioactive flavonoid metabolites retaining or exceeding the antioxidative and anti-inflammatory properties of the intact flavonoid and, in some cases, new antitumor and antineurodegenerative bioactivities. Certain food items have been identified with high prebiotic profiles suggesting that neutraceutical supplementation may be beneficially employed to preserve a healthy population of bacterial symbiont species and minimize the establishment of harmful pathogenic organisms. Gut health is an important consideration effecting the overall health and wellbeing of linked organ systems. Bioconversion of dietary flavonoid components in the gut generates therapeutic metabolites that can also be transported by the vagus nerve and systemic circulation to brain cell populations to exert a beneficial effect. This is particularly important in a number of neurological disorders (autism, bipolar disorder, AD, PD) characterized by effects on moods, resulting in depression and anxiety, impaired motor function, and long-term cognitive decline. Native flavonoids have many beneficial properties in the alleviation of inflammation in tissues, however, concerns have been raised that therapeutic levels of flavonoids may not be achieved, thus allowing them to display optimal therapeutic effects. Dietary manipulation and vagal stimulation have both yielded beneficial responses in the treatment of autism spectrum disorders, depression, and anxiety, establishing the vagal nerve as a route of communication in the gut-brain axis with established roles in disease intervention. While a number of native flavonoids are beneficial in the treatment of neurological disorders and are known to penetrate the blood-brain barrier, microbiome-generated flavonoid metabolites (e.g., protocatechuic acid, urolithins, ?-valerolactones), which retain the antioxidant and anti-inflammatory potency of the native flavonoid in addition to bioactive properties that promote mitochondrial health and cerebrovascular microcapillary function, should also be considered as potential biotherapeutic agents. Studies are warranted to experimentally examine the efficacy of flavonoid metabolites directly, as they emerge as novel therapeutic options.
引用
收藏
页数:47
相关论文
共 47 条
  • [41] Novel inhibitors of the high-affinity L-proline transporter as potential therapeutic agents for the treatment of cognitive disorders
    Zipp, G. Greg
    Barbosa, Joseph
    Green, Michael A.
    Terranova, Kristen M.
    Fink, Cynthia
    Yu, Xuan-Chuan
    Nouraldeen, Amr
    Wilson, Alan
    Savelieva, Katerina
    Lanthorn, Thomas H.
    Kimball, S. David
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (16) : 3886 - 3890
  • [42] The therapeutic potential of metabolic hormones in the treatment of age-related cognitive decline and Alzheimer's disease
    Grizzanti, John
    Lee, Hyoung-Gon
    Camins, Antoni
    Pallas, Merce
    Casadesus, Gemma
    [J]. NUTRITION RESEARCH, 2016, 36 (12) : 1305 - 1315
  • [43] Bringing natural products into the fold - exploring the therapeutic lead potential of secondary metabolites for the treatment of protein-misfolding-related neurodegenerative diseases
    Joyner, P. Matthew
    Cichewicz, Robert H.
    [J]. NATURAL PRODUCT REPORTS, 2011, 28 (01) : 26 - 47
  • [44] Principles of Design of Clinical Trials for Prevention and Treatment of Alzheimer's Disease and Aging-Associated Cognitive Decline in the ACH2.0 Perspective: Potential Outcomes, Challenges, and Solutions
    Volloch, Vladimir
    Rits-Volloch, Sophia
    [J]. JOURNAL OF ALZHEIMERS DISEASE REPORTS, 2023, 7 (01) : 921 - 955
  • [45] A berry thought-provoking idea: the potential role of plant polyphenols in the treatment of age-related cognitive disorders
    Cherniack, E. Paul
    [J]. BRITISH JOURNAL OF NUTRITION, 2012, 108 (05) : 794 - 800
  • [46] The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality
    Zhou, Yanling
    Wang, Chengyu
    Lan, Xiaofeng
    Zheng, Wei
    Li, Hanqiu
    Chao, Ziyuan
    Wu, Kai
    McIntyre, Roger S.
    Ning, Yuping
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 2021, 144 : 312 - 319
  • [47] Novel 1H-Pyrrolo[3,2-c]quinoline Based 5-HT6 Receptor Antagonists with Potential Application for the Treatment of Cognitive Disorders Associated with Alzheimer's Disease
    Grychowska, Katarzyna
    Satala, Grzegorz
    Kos, Tomasz
    Partyka, Anna
    Colacino, Evelina
    Chaumont-Dubel, Severine
    Bantreil, Xavier
    Wesolowska, Anna
    Pawlowski, Maciej
    Martinez, Jean
    Marin, Philippe
    Subra, Gilles
    Bojarski, Andrzej J.
    Lamaty, Frederic
    Popik, Piotr
    Zajdel, Pawel
    [J]. ACS CHEMICAL NEUROSCIENCE, 2016, 7 (07): : 972 - 983